Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab

Fig. 2

Graphic presentation of the difference in expression of each of the eight genes with statistical significance (defined by p value < 0.05) in discriminating patients who develop grades 0–1 versus 2–4 diarrhea. T-test analysis performed on blood samples obtained 30 days post initiation of tremelimumab treatment

Back to article page